Abstract 844P
Background
The objective of this study is to apply machine learning (ML) models to multiple myeloma(MM) patient-level data to evaluate if ML models can identify high-risk features linked to faster disease progression.
Methods
Data for 15,931 MM patients in France, Spain, UK, Germany, and Italy were extracted from Oncology Dynamics (OD), a large cross-sectional survey that collects drug-treated patient-level data through a panel of cancer specialists. The analyses include 6 years (2017-2022) of records. Progression-free survival (PFS) was measured as the time from start of therapy to date of progression. The underlying data included treatment regime, line of therapy (LOT), ECOG status, stem cell transplant (SCT) eligibility, Durie-Salmon stage, cytogenetic risk, and age and gender. Machine Learning-based survival models (Gradient Boosted Survival Trees, Random Survival Forest) were applied to predict outcomes. Additionally, Shapley values were calculated to assess the model’s decision making and identify key risk drivers.
Results
Data was split into Training (80%) and Test Data (20%). The output of the model was the ML derived risk score: higher risk score was associated with shorter PFS. Model performance was good (Harrell’s C-Index = 0.741). Data shows that higher LOTs and not being eligible for SCT are associated with increased risk of disease progression. Inversely, being in the 1st LOT, ECOG asymptomatic and certain drug regimens (e.g., Lenalidomide or Dexamethasone/Lenalidomide) are associated with longer PFS.
Conclusions
This is a first successful step in leveraging OD data for the development of a prognostic score for MM patients using machine learning algorithms. ML models applied to secondary market research can support optimal disease management and planning of clinical trials. Also, given the heterogeneity of treatment plans across Europe, further investigation into country-specific differences in PFS may be studied.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA.
Funding
Has not received any funding.
Disclosure
M.L. Pleguezuelo Witte, M. Muller, J. Hartmann, C. Ricarte, T. Moehler, M. Lopez, K. Jindal: Financial Interests, Personal, Full or part-time Employment: IQVIA.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18